The Journal of the American Academy of Dermatology published an ethics analysis on October 13, 2026, titled "Between Advocacy and Deception: The Ethics of Diagnostic Code Manipulation and Severity Inflation in Dermatology." Joshua K. Morales and Jane M. Grant-Kels authored the paper, which is now available online.

The title alone signals the stakes. The authors place two practices under the ethical microscope: diagnostic code manipulation and severity inflation. Both sit at the uneasy intersection of patient advocacy and documentation integrity, and both carry consequences that reach from the exam room to the payer.

Why does this paper land now?

Dermatology runs on coded language. A psoriasis encounter documented as moderate rather than mild, or an eczema visit framed with a complication code, can change what a patient can access — and what a practice can bill.

The paper's framing, "between advocacy and deception," names the tension directly. Clinicians sometimes shade a code to secure coverage for a therapy they believe a patient needs. Payers and auditors read the same act as misrepresentation.

Morales and Grant-Kels engage that boundary in a peer-reviewed JAAD ethics format, which gives the question institutional weight it rarely gets outside compliance seminars.

What's actually at issue?

The paper's subject matter breaks into the components its title declares:

• Diagnostic code manipulation — selecting or altering diagnosis codes in ways that diverge from the documented clinical reality.
• Severity inflation — describing a condition as more severe than the record supports, whether to justify treatment intensity, secure prior authorization, or support reimbursement.
• The advocacy defense — the argument that coding flexibility serves patients facing coverage barriers.
• The deception charge — the counterargument that inaccurate coding constitutes fraud, distorts data, and exposes clinicians to audit and penalty.

The authors treat these as ethical questions rather than mere compliance mechanics, per the paper's stated scope.

Why should dermatologists care?

Because the practices in question aren't hypothetical in this specialty. Dermatology's prior-authorization environment pressures documentation daily — biologic approvals for psoriasis, step-therapy escalation for atopic dermatitis, and lesion characterization in skin-cancer care all hinge on how severity and diagnosis get coded.

When an ethics paper in JAAD takes up severity inflation, it moves the conversation from informal workarounds to the literature. Grant-Kels, a longtime JAAD ethics contributor, and Morales are placing the question before the specialty's flagship journal at a moment when payer friction over dermatologic therapy access remains high.

The stakes cut both ways. Code too conservatively and a patient may lose access to therapy. Code generously and the clinician risks audit exposure, with the paper's title itself conceding how fine that line can run.

What comes next?

The analysis is available online as of October 13, 2026, and dermatologists who code, document, or prior-authorize — which is nearly all of them — will find its central question hard to dodge: whether any degree of severity inflation can be defended as advocacy, or whether accuracy must hold regardless of payer behavior. How journals, societies, and compliance bodies respond to that question will shape coding norms in the specialty for years.